Bristol-Myers profit slightly tops Wall Street view on blood thinner sales
U.S drugmaker Bristol-Myers Squibb Co, which is set to buy biotechnology company Celgene Corp for $74 billion, posted slightly better-than-expected first-quarter earnings on Thursday on strong sales of its blockbuster blood thinner Eliquis. Bristol-Myers said it still expects full-year adjusted earnings